1h Free Analyst Time
The janus kinase (JAK) inhibitors market is forecasted to grow by USD 15.57 billion during 2023-2028, accelerating at a CAGR of 20.6% during the forecast period. The report on the janus kinase (JAK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing number of awareness campaigns on autoimmune disorders, application of jak inhibitors in severe chronic indications, and support from growing healthcare insurance industry.
The janus kinase (JAK) inhibitors market is segmented as below:
By Application
- Autoimmune disorders
- Oncology
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the janus kinase (JAK) inhibitors market covers the following areas:
- Janus Kinase (JAK) Inhibitors Market sizing
- Janus Kinase (JAK) Inhibitors Market forecast
- Janus Kinase (JAK) Inhibitors Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global janus kinase (JAK) inhibitors market: AbbVie Inc., Alexion Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., CTI BioPharma Corp., Eli Lilly and Co., Galapagos NV, Gilead Sciences Inc., GlaxoSmithKline Plc, Incyte Corp., Novartis AG, Pfizer Inc., Reistone Biopharma Co. Ltd., and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing number of research grants."
According to the report, one of the major drivers for this market is the increasing number of awareness campaigns on autoimmune disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alexion Pharmaceuticals Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bristol Myers Squibb Co.
- CTI BioPharma Corp.
- Eli Lilly and Co.
- Galapagos NV
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Incyte Corp.
- Novartis AG
- Pfizer Inc.
- Reistone Biopharma Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
